Topic: bone marrow transplant
The week’s news included antibodies that lower the risks of bone marrow transplants and a new way to target a mutation in epilepsy.
Magenta’s MGTA-456 hit efficacy targets in the first patients from a phase 2 trial that will drop at ASH next month, but with a question about safety.
The week’s biotech news included a potential boost to cancer immunotherapy and new insight into a dementia-causing protein.
Kalytera is developing cannabidiol for the prevention and treatment of graft-versus-host disease, a serious complication of bone marrow transplant.
Coming off the back of a healthy financing round just six weeks ago, stem cell biotech Magenta Therapeutics now wants more, and it wants to go public.
Semma Therapeutics named Bastiano Sanna, formerly of Novartis’ cell and gene therapy unit and Magenta Therapeutics, as its president and CEO.
Magenta could pay the German biotech up to $334 million in milestones if the antibody drug conjugate pacts hit their targets.